On June 24, the major share holder of Ardelyx Inc. (NASDAQ:ARDX), CMEA Ventures VII LP, purchased a total of 316,826 shares of the company in the open market. The average price of these shares was reported to be around $14. The company’s weekly performance is 29.94% whereas its net profit margin is -33 percent. On the last trade day, the company was able to close its shares at the price of $20.44.

On May 8, 2014, Synta Pharmaceuticals Corp. (NASDAQ:SNTA) updated the public on its recent events. Moreover the company disclosed its financial reports for the first quarter of the year. As for the revenues section, no revenues were reported for the first quarter of the year 2014. However, the company incurred an expense of $17.6 million during the first quarter for its research activities. It is pertinent to note here that the company’s expenses for the same category were $16.4 million a year back. Coming to the Administrative and General expenses, the figures rose from 3.9 million to $5.3 million in a matter of one year. Moreover, the company’s reported net loss was $23.6 million; during the same quarter of 2013, the company’s net loss was $20.7 million.

In the last trading session, the company’s shares closed at the price of $4.50 with a weekly performance of 11.66 percent and SMA50 of 7.80 percent. Analyst firms have given the company an average target price of 13.92.

Talking about Arca Biopharma Inc (NASDAQ:ABIO), the company held its 2014 Annual General Meeting on June 5, 2014. During this meeting, the shareholders were to vote for the Board of Director’s nominees, and they had to decide between Robert E. Conway and Michael R. Bristow. Moreover, the company put forward a resolution for the ratification of its contract with KPMG LLP. KPMG LLP was acting as company’s accounting firm for the year 2014.

On the last trading day, Arca Biopharma Inc (NASDAQ:ABIO)’s shares jumped up by 8.78 percent and closed at a price of $1.61.  The company’s quarterly performance was recorded to be at -13.90% whereas its returns on assets were -51.20%.

Coming to Athersys, Inc (NASDAQ:ATHX), the share prices of company increased by 6.59% when Zacks, a business and financial advisory firm, updated the company’s ratings to ‘neutral’ from ‘underperform’, on Monday via research report. The company’s current target price is $1.80. On the last trade day, Athersys, Inc. (NASDAQ:ATHX) was able to close its shares at $1.94, with an intra-day range of $1.87 to $1.96. Company’s YTD is -22.40%.

On June 19, 2014, Relypsa, Inc. (NASDAQ:RLYP) held its Annual General Meeting for the year 2014. During this meeting, a resolution was put forward whereby Kenneth J. Hillan, chief executive officer and president of the company, and Daniel K. Spiegelman, chief financial officer and vice president of the company were made members of the Board of Directors. On the last trading day, the company was able to close its shares at the price of $26.33, with a weekly performance of 9.89%. As far as company’s price to cash and weekly volatility ratios are concerned, these are 11.29 and 6.19% respectively.

Get Free Updates and Stock Alerts!

*We only send one email per week